On January 30, 2019, Abivax hosted a KOL lunch event focused on promising clinical development of ABX464 in Ulcerative Colitis and HIV.

A replay of the webcast is available here: http://abivax.streameo.fr/live.html

Share Profile

Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.

  • ISIN code: FR0012333284
  • Symbol: ABVX
  • ICB Classification: Healthcare 4000/ Biotechnology 4573
  • Market: Euronext Paris-Compartment C
  • Type of Listing: continuous
  • Number of outstanding shares: 10,199,182 as of 30 September 2018
  • Indicies: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
  • Eligible to French PEA PME

Analysts

Goetz Partners:

Chris Redhead

Contact Chris Redhead

NIBC:

Dylan van Haaften & Anita Ye

Contact Dylan van Haaften / Contact Anita Ye

Royal Bank of Canada:

Douglas Miehm

Contact Douglas Miehm

LifeSci Capital:

David Sherman & Sam Slutsky

Contact David Sherman / Contact Sam Slutsky</a

Investor Contact

Chris Maggos LifeSci Advisors Chris@lifesciadvisors.com +41 79 367 6254